Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Storm Therapeutics Extends Series A To GBP 30m (usd 38.43m) With New Investor, Seroba Life Sciences

by posted 4months ago 60 views
CAMBRIDGE, England, May 20, 2019-- STORM Therapeutics ("STORM"), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional £14 million bringing the total Series A financing to £30 million. The financing includes funding from new investor, Seroba Life Sciences ("Seroba"). STORM's existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise. This extension follows the company's rapid progress to date.